Abstract
Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.
| Original language | English |
|---|---|
| Pages (from-to) | 401-405 |
| Number of pages | 5 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 8 |
| Issue number | 5 |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. / Bajetta, E.; Buzzoni, R.; Viviani, S.; Vaglini, M.; Nava, M.; Bonadonna, G.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 8, No. 5, 1985, p. 401-405.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine
AU - Bajetta, E.
AU - Buzzoni, R.
AU - Viviani, S.
AU - Vaglini, M.
AU - Nava, M.
AU - Bonadonna, G.
PY - 1985
Y1 - 1985
N2 - Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.
AB - Thrity-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B). In 31 evaluable patients, Regimen A induced an overall response rate of 31% and a complete response rate of 6%; with Regimen B the corresponding findings were 20% and 20%, respectively. The median duration of complete response was 12 months with both regimens and the comparative median total survivals were 8 and 6 months, respectively. In no case was toxicity so severe to require treatment discontinuation, and the major dose-limiting side effect was myelosuppression, especially in the patients treated with Regimen B. Present results confirm once more the limited activity of drugs and regimens presently utilized in the treatment of advanced malignant melanoma.
UR - http://www.scopus.com/inward/record.url?scp=0022406222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022406222&partnerID=8YFLogxK
M3 - Article
C2 - 3904398
AN - SCOPUS:0022406222
VL - 8
SP - 401
EP - 405
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 5
ER -